Abstract
Owing to the specific and high binding affinity of aptamers to their targets, aptamer–drug conjugates (ApDCs) have emerged as a promising drug delivery system for targeted cancer therapy. However, in a conventional ApDC, the aptamer segment usually just serves as a targeting moiety, and only a limited number of drug molecules are sequentially conjugated to the oligonucleotide, giving a relatively low drug loading capacity. To address this challenge, herein we employ four clinically approved nucleoside analogues, including clofarabine (Clo), ara-guanosine (AraG), gemcitabine (Ge), and floxuridine (FdU), to replace all natural nucleosides in aptamer sequences, generating a series of whole drug-constituted DNA-like oligomers that are termed drugtamers. Similar to their parent aptamers, the obtained drugtamers maintain the targeting capability and can specifically bind to the target receptors overexpressed on the cancer cell surface. With 100% drug loading ratio, active targeting capability, and enzyme-mediated release of active therapeutics, our drugtamers can strongly induce the apoptosis of cancer cells and inhibit the tumor progression, which enables a new potential for a better targeted cancer therapy.
Funding Information
  • Ministry of Science and Technology of the People's Republic of China (2018YFA0902600, 2018YFC1106102)
  • Science and Technology Commission of Shanghai Municipality (18JC1410800, 19JC1410300)
  • National Natural Science Foundation of China (21805129, 21905170, 22175116, 51690151, 51973112)

This publication has 34 references indexed in Scilit: